ACC vs AMBUJACEM
Side-by-side comparison of ACC Ltd. and Ambuja Cements Ltd.. Descriptive only — not investment advice.
ACC Ltd.
Cement
Quality Score: 42/100
Ambuja Cements Ltd.
Cement
Quality Score: 43/100
At a glance
| Metric | ACC | AMBUJACEM |
|---|---|---|
| Quality Score | 42/100 | 43/100 |
| P/E (trailing) | 12.0 | 22.9 |
| Forward P/E | 11.4 | 28.0 |
| ROE | +10.9% | +8.3% |
| Profit margin | +8.2% | +11.6% |
| Debt-to-equity | 2.08 | 1.21 |
| Dividend yield | +0.54% | +0.45% |
| 1Y price return | -30.6% | -22.3% |
| From 52w high | -33.0% | -30.4% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.42 | 1.98 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
ACC trades at ₹1,360, down 30.56% over 12 months and 32.97% below its 52-week high, with price below both the 50-DMA (₹1,385.63) and 200-DMA (₹1,672.18). Q4 FY26 revenue rose 17% to a record level while net profit fell 68% YoY, reflecting cost pressure that has compressed 5-year earnings growth to -68.3% even as the 5-year revenue CAGR stands at 17.8%.
Ambuja Cements (NSE: AMBUJACEM) is a large-cap cement producer trading at Rs 434.90 as of the run date, down 22.28% over 12 months and 30.41% below its 52-week high, with both the 50-DMA (Rs 438.76) and 200-DMA (Rs 519.98) acting as overhead levels. The trailing PE stands at 22.85 against a cement-sector peer range of 12.0-51.9, while ROE of 8.31% has not cleared 15% in any tracked year and FCF was positive in only 1 of the tracked years. Mean analyst rating of 1.97 across 41 analysts (1-5 scale, lower = more constructive).
Pros
- ✓Lowest trailing PE among 6 tracked cement peers at 11.98x versus a sector range of 22.9x (AMBUJACEM) to 51.9x (SHREECEM), with forward PE at 11.41x.
- ✓Highest ROE among cement peers with available data at 10.93% versus ULTRACEMCO 10.59%, AMBUJACEM 8.31%, DALBHARAT 6.50%, and GRASIM 6.29%.
- ✓5-year revenue CAGR of 17.8% with Q4 FY26 recording the highest-ever sales volumes, indicating operational throughput capacity is intact.
- ✓Quality score of 32/100 ranks 2nd among the 6 tracked sector peers; mean analyst rating of 2.41 across 31 analysts (1–5 scale, lower = more constructive).
- ✓Revenue has grown at a 5-year CAGR of 9.4%, reflecting the company's scale as one of India's top-3 cement producers by capacity.
- ✓Trailing PE of 22.85 is the second-lowest among the 6 tracked cement peers (range 12.0-51.9), indicating compressed valuation relative to the sector median.
- ✓Q4 2026 net profit was reported at +78.5% YoY, and Devdiscourse coverage cited strategic capacity expansion efforts alongside the profit headline.
- ✓Dividend yield of 0.45% and RSI of 45.1 (neutral band) indicate neither extreme momentum nor dividend distress at current prices.
Cons
- ✗5-year earnings growth of -68.3% with FCF positive in only 1 of the tracked years; profitability has deteriorated sharply even as revenue scale expanded.
- ✗Price is 30.56% lower over 12 months and 32.97% below the 52-week high; below both the 50-DMA and 200-DMA, with the gap to the 200-DMA at approximately 23%.
- ✗D/E of 2.09 on a rising debt trend with ROE never exceeding 15% in the tracked period (roeYearsAbove15 = 0) and a consistency score of 34/100.
- ✗Production stoppage at the Jhinkpani plant affecting ~1,500 workers (reported May 2026) adds operational uncertainty to an already cost-pressured earnings profile.
- ✗ROE of 8.31% has not exceeded 15% in any single tracked year, and the persistence consistency score is 0 — returns on capital have been structurally low.
- ✗FCF was positive in only 1 of the tracked years, and D/E of 1.21 is on a rising trend, pointing to elevated and growing capital requirements relative to cash generation.
- ✗The stock has been below the 200-DMA for an extended period, currently 16.4% beneath that level (Rs 519.98), with a 30.41% drawdown from the 52-week high — the largest absolute price decline among the tracked peer set.
- ✗Q4 2026 EBITDA margins were under pressure; the strong net profit figure was driven by a tax benefit rather than operating leverage, creating a divergence between headline and operating earnings quality.
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.